MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

This policy covers non-NGS multi-gene panel testing and limited single-gene testing for the diagnostic evaluation of BCR-ABL-negative myeloproliferative neoplasms (classical: PV, ET, PMF; non-classical: CNL, CEL NOS) when performed per consensus diagnostic criteria. Coverage requires prior BCR-ABL assessment (except when only PV is suspected), use of analytically sensitive assays meeting a minimum VAF detection threshold, appropriate reflex sequencing or minimum gene panel content (JAK2, CALR, MPL; add CSF3R for CNL; include AML-associated genes if blast/accelerated PMF suspected), completion of technical assessment and peer-reviewed clinical validity, and testing solely for diagnostic purposes (not for MRD or test-of-cure).

"Coverage is provided for multi-gene non-next generation sequencing (non-NGS) panel testing for the diagnostic workup of BCR-ABL-negative myeloproliferative neoplasms (MPNs), including classical (PV..."